ArticleOpen forum infectious diseases2023

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.

José R Santos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.